Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: 15th International Conference on Human Retroviruses: HTLV and Related Viruses

Open Access Open Badges Meeting abstract

A prototype RT-PCR assay for detection of XMRV in multiple human sample types

Ning Tang1*, Andrea Frank1, Robert Kowal1, Gregor Leckie1, John Hackett2, Graham Simmons3, Michael Busch3 and Klara Abravaya1

Author Affiliations

1 Abbott Molecular Inc., Des Plaines, IL, 60018, USA

2 Abbott Diagnostics, Abbott Park, North Chicago, Illinois, 60064, USA

3 Blood Systems Research Institute, University of California, San Francisco, CA, 94118, USA

For all author emails, please log on.

Retrovirology 2011, 8(Suppl 1):A220  doi:10.1186/1742-4690-8-S1-A220

The electronic version of this article is the complete one and can be found online at:

Published:6 June 2011

© 2011 Tang et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Xenotropic murine leukemia virus-related virus (XMRV) has been reported to be associated with prostate cancer and chronic fatigue syndrome. To help resolve the role of XMRV in human disease, it is critical to develop sensitive and accurate PCR assays for XMRV detection.

Materials and methods

The automated m2000 system RT-PCR assays detect the pol and env regions of XMRV in whole blood, plasma, urine, and cell pellets. Assay performance was assessed by testing two blinded panels prepared by the Blood XMRV Scientific Research Working Group (SRWG), as well as clinical specimens.


For the SRWG whole blood panel, all six XMRV negative samples were assay negative, while all the 22Rv1-spiked samples from 0.5 cells/mL to 9,900 cells/mL were detected (3/3 for each panel member). For the SRWG plasma panel, all six XMRV negative samples were assay negative, while the 22Rv1 supernatant-spiked plasma samples were detected as positive, 1/3 for the 3.2 XMRV copies/mL panel member, 2/3 for the 16 copies/mL panel member, and 3/3 for panel members containing > 80 copies/mL. For screening of clinical specimen, assay positive results were obtained for 10% (2/20) of prostate cancer FFPE specimens, 0.5% (2/400) of prostate cancer urine pellets, and 0% (0/135) of the cervical swab specimens.


We developed an automated high throughput real-time RT-PCR assay (with internal control) to detect XMRV. Use of this assay should assist in elucidation of the role of XMRV in human disease.